Hims & Hers Health, Inc.
48.23-0.55 (-1.13%)
Oct 27, 4:00:02 PM EDT · NYSE · HIMS · USD
Key Stats
Market Cap
10.90BP/E (TTM)
61.05Basic EPS (TTM)
0.79Dividend Yield
0%Recent Filings
8-K
Hims leases Ohio facility
Hims & Hers Health subsidiary Hims inked a 15-year lease on September 1, 2025, for 352,012 square feet at 9885 Innovation Campus Way in New Albany, Ohio, earmarked for office, R&D, lab, manufacturing, and pharma dispensing. Base rent kicks off at $5.98M annually from April 2026, with full abatement until then and partial relief for five months after, plus two five-year extensions possible. This bolsters production capacity, yet ties up hefty upfront security via a $5.98M letter of credit.
8-K
Q2 revenue soars 73%
Hims & Hers Health reported Q2 2025 revenue of $544.8 million, surging 73% year-over-year, fueled by subscribers hitting 2.4 million—up 31%—and monthly online revenue per average subscriber climbing 30% to $74. Net income jumped to $42.5 million while Adjusted EBITDA more than doubled to $82.2 million, though gross margin dipped to 76% amid weight loss expansion. The company affirmed full-year guidance of $2.3–$2.4 billion in revenue and $295–$335 million in Adjusted EBITDA, eyeing international growth via ZAVA acquisition. Free cash flow turned negative at $(69.4) million due to capex; resolution of semaglutide shortage poses supply risks.
10-Q
Q2 FY2025 results
Hims & Hers Health posted strong Q2 FY2025 results, with revenue surging 73% y/y to $544.8M, fueled by GLP-1 weight loss offerings that drove subscriber growth to 2.4M, up 31% y/y. Gross margin dipped to 76% from 81% y/y amid higher costs for new products, yet operating income climbed to $26.7M, a 142% y/y jump, while diluted EPS rose to $0.17 from $0.06, reconciling cleanly with 256.8M weighted shares. Cash swelled to $1.1B after issuing $1.0B convertible notes due 2030 at 0% interest, maturing May 2030, with $174M available on a $175M revolver; free cash flow turned negative at -$69.4M (derived) from capex on facilities. Acquisitions bolstered supply chain, including February's $39.1M peptide assets (cash/stock) and $5.1M lab testing buy, recognizing $5.0M goodwill. Regulatory shifts on compounded GLP-1s pose supply risks.
8-K
Annual meeting results
Hims & Hers Health held its annual stockholder meeting on June 12, 2025, where investors elected all eight nominated directors, including Andrew Dudum and seven others, with overwhelming support—over 98% votes for most, despite some withheld shares. Stockholders ratified KPMG LLP as auditors for the fiscal year ending December 31, 2025, with 99.9% approval, and gave advisory nod to executive compensation at 98.3%. Board continuity solidified. No surprises here.
8-K
Hims issues $1B convertible notes
Hims & Hers Health issued $1.0 billion in 0.00% Convertible Senior Notes due 2030 on May 13, 2025, via a private Rule 144A offering, with an initial conversion rate of 14.1493 shares per $1,000 principal—equating to $70.67 per share. The notes mature in 2030, convertible under specific conditions, and rank senior unsecured, bolstering the balance sheet for growth while capping dilution through $47.8 million in accompanying capped call transactions at $89.95 per share. Yet dilution risks persist if conversions exceed caps.
IPO
Website
Employees
Sector
Industry